Valuation: Aclarion, Inc.

Market Cap 7.26M 6.35M 5.86M 5.42M 10.29M 693M 10.46M 70.17M 27.51M 340M 27.27M 26.68M 1.18B P/E 2026 *
-0.65x
P/E 2027 * -0.53x
Enterprise Value 7.26M 6.35M 5.86M 5.42M 10.29M 693M 10.46M 70.17M 27.51M 340M 27.27M 26.68M 1.18B EV / Sales 2026 *
53.8x
EV / Sales 2027 * 28.3x
Free-Float
73.8%
Yield 2026 *
-
Yield 2027 * -
1 day-1.36%
1 week-3.64%
Current month+1.04%
1 month-13.39%
3 months-18.49%
6 months-64.38%
Current year-36.74%
1 week 2.84
Extreme 2.84
3.17
1 month 2.62
Extreme 2.62
3.49
Current year 2.34
Extreme 2.3401
9.36
1 year 2.34
Extreme 2.3401
12.03
3 years 2.34
Extreme 2.3401
112,881.52
5 years 2.34
Extreme 2.3401
586,115.57
10 years 2.34
Extreme 2.3401
586,115.57
Manager TitleAgeSince
Chief Executive Officer 59 2021-09-14
Director of Finance/CFO 60 2025-09-01
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 69 2015-12-31
Director/Board Member 55 2016-08-31
Chairman 61 2022-04-20
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Director

20,000 0.8123%
06-10Free

Chief Financial Officer

50,000 2.0307%
06-10Free

Director

20,000 0.8123%
Change 5-day change 1-year change 3-year change Capi.($)
-1.36%-3.64%-61.76%-100.00% 7.26M
+1.68%+3.55%+4.86%+10.97% 49.42B
+0.72%+1.93%+424.51%+624.25% 40.34B
+2.54%+2.84%+27.06%-3.62% 34.01B
+0.31%+4.16%+23.87%+59.76% 33.56B
-2.09%-0.80%+3.56%+33.56% 26.84B
-0.63%+2.85% - - 17.22B
+0.66%-1.48%+66.05%+127.36% 15.19B
-23.90%-18.84%+55.47%+53.83% 13.96B
+2.59%+0.50%+15.28%+21.25% 13.36B
Average -1.95%+0.51%+62.10%+91.93% 24.39B
Weighted average by Cap. -0.60%+0.90%+93.36%+138.86%

Financials

2026 *2027 *
Net sales 135K 118K 109K 101K 191K 12.89M 194K 1.3M 511K 6.33M 507K 496K 21.92M 257K 225K 207K 192K 364K 24.53M 370K 2.48M 973K 12.05M 965K 944K 41.73M
Net income -10.71M -9.37M -8.64M -7.99M -15.17M -1.02B -15.42M -103M -40.55M -502M -40.2M -39.33M -1.74B -13.47M -11.78M -10.86M -10.05M -19.08M -1.29B -19.4M -130M -51M -631M -50.56M -49.46M -2.19B
Net Debt - -
Logo Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Employees
11
Date Price Change Volume
26-07-09 US$2.910 -1.36% 43,251
26-07-08 US$2.950 -1.34% 31,060
26-07-07 US$2.990 -2.61% 55,931
26-07-06 US$3.070 -0.65% 20,371
26-07-02 US$3.090 +2.32% 21,273
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.910USD
Average target price
7.500USD
Spread / Average Target
+157.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACON Stock